 |
|
 |
 |

Home > Company Index > Drugs > Diagnostic Substances > Genelabs Technologies, Inc.
 |
Genelabs Technologies, Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Brazil's Varig posts 1st-half loss of 509 mln reais Aug 14 2001 05:55 AM PDT
D.Telekom surges after upgrade, leading DAX rally Aug 14 2001 04:25 AM PDT
> More WIRE STORIES about this company
PROFILE |
 |
In the war against bacterial resistance to antibiotics, Genelabs Technologies targets disease at the source, developing small-molecule drugs that bind to DNA and change the activity of disease-causing genes. Its MERLIN technology identifies molecules' DNA-binding preferences and, ultimately, which sequences will host DNA-binding drugs. Applications include cancer therapies and treatments for bacterial and viral infections. The company is awaiting FDA approval for Aslera, a new therapy for lupus. Genelabs also researches genetic technologies for use against biological warfare agents. Subsidiary Genelabs Diagnostics makes diagnostic test kits, reagents, and equipment.
COMPETITION |
 |
Enzo Biochem, Inc. (ENZ)
Hybridon, Inc. (HYBN)
OSI Pharmaceuticals, Inc. (OSIP)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 7.10
1-Yr. Sales Growth: (11.3)%
Employees: 90
Revenue per employee: $78,888.89
KEY PEOPLE |
 |
Irene A. Chow
CEO
Matthew M. Loar
CFO
CONTACT INFO |
 |
505 Penobscot Dr.
Redwood City, CA 94063
US
Phone: 650-369-9500
Fax: 650-368-0709
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |